Wang, Hao
Sica, R. Alejandro
Kaur, Gurbakhash
Galbo, Phillip M. Jr http://orcid.org/0000-0002-5391-598X
Jing, Zhixin http://orcid.org/0000-0003-1118-7432
Nishimura, Christopher D.
Ren, Xiaoxin
Tanwar, Ankit
Etemad-Gilbertson, Bijan
Will, Britta
Zheng, Deyou http://orcid.org/0000-0003-4354-5337
Fooksman, David
Zang, Xingxing http://orcid.org/0000-0001-5380-1942
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Information Technology (R01CA262132, R01CA175495)
U.S. Department of Defense (PC210331)
U.S. Department of Health & Human Services | NIH | Center for Information Technology
Article History
Received: 19 September 2022
Accepted: 21 November 2023
First Online: 2 January 2024
Competing interests
: The authors declare the following competing interests. H.W., R.A.S., and X.Z. are inventors on a pending patent (Compositions and methods for inhibiting the expression of TMIGD2); B.E.-G. is an employee and X.Z. is the scientific co-founder of NextPoint Therapeutics. All other authors declare no competing interests.